Showing results (581-590 of 632) with videos related to

Sort By:
Pageof 64
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|April 25, 2019
Tolerance doses for late adverse events after hypofractionated radiotherapy for prostate cancer on trial NRG Oncology/RTOG 0415Maria Thor, Joseph O Deasy, Rebecca Paulus, et al.
JCO Precision Oncology|October 24, 2024
Prostate Cancer Risk Stratification in NRG Oncology Phase III Randomized Trials Using Multimodal Deep Learning With Digital HistopathologyJonathan David Tward, Huei-Chung Huang, Andre Esteva, et al.
International Journal of Radiation Oncology, Biology, Physics|December 17, 2021
Quality of Life Implications of Dose-Escalated External Beam Radiation for Localized Prostate Cancer: Results of a Prospective Randomized Phase 3 Clinical Trial, NRG/RTOG 0126William A Hall, Snehal Deshmukh, Deborah W Bruner, et al.
Urology|August 2, 2008
A multi-institutional matched-control analysis of adjuvant and salvage postoperative radiation therapy for pT3-4N0 prostate cancerEdouard J Trabulsi, Richard K Valicenti, Alexandra L Hanlon, et al.
International Journal of Radiation Oncology, Biology, Physics|September 4, 2021
Adding Short-Term Androgen Deprivation Therapy to Radiation Therapy in Men With Localized Prostate Cancer: Long-Term Update of the NRG/RTOG 9408 Randomized Clinical TrialChristopher U Jones, Stephanie L Pugh, Howard M Sandler, et al.
International Journal of Radiation Oncology, Biology, Physics|January 3, 2023
Analysis of a Biopsy-Based Genomic Classifier in High-Risk Prostate Cancer: Meta-Analysis of the NRG Oncology/Radiation Therapy Oncology Group 9202, 9413, and 9902 Phase 3 Randomized TrialsPaul L Nguyen, Huei-Chung Rebecca Huang, Daniel E Spratt, et al.
Lancet (London, England)|May 15, 2022
The addition of androgen deprivation therapy and pelvic lymph node treatment to prostate bed salvage radiotherapy (NRG Oncology/RTOG 0534 SPPORT): an international, multicentre, randomised phase 3 trialAlan Pollack, Theodore G Karrison, Alexander G Balogh, et al.
European Urology Oncology|July 17, 2025
Transcriptomic Analysis of Localized High-risk Prostate Cancer Improves Prognostication and Identifies Benefit from Adding Docetaxel to Definitive Radiotherapy with Androgen Suppression in the NRG Oncology/RTOG 0521 Phase 3 TrialRyan M Phillips, James A Proudfoot, Elai Davicioni, et al.
JCO Clinical Cancer Informatics|July 1, 2022
Methodological Comparison of Mapping the Expanded Prostate Cancer Index Composite to EuroQoL-5D-3L Using Cross-Sectional and Longitudinal Data: Secondary Analysis of NRG/RTOG 0415Rahul Khairnar, Lyudmila DeMora, Howard M Sandler, et al.
Cancer|December 29, 2022
Body composition and mortality in men receiving prostate radiotherapy: A pooled analysis of NRG/RTOG 9406 and NRG/RTOG 0126Andrew M McDonald, Lyudmila DeMora, Eddy S Yang, et al.
Pageof 64